Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanita' (ISS), via Giano della Bella 34, 00162 Rome, Italy.
Drug Discov Today. 2012 Oct;17(19-20):1139-46. doi: 10.1016/j.drudis.2012.06.004. Epub 2012 Jun 15.
Several classes of drugs that we refer to here as 'promoter drugs' can improve tumor uptake and penetration of other drugs that we refer to as 'effector drugs', which exert direct antitumor effects. In this review we discuss the main therapeutic advantages that can be obtained by using promoter drugs. First, tumor-specific enhancement of effector drug accumulation but unaltered accumulation in normal tissues with improvement of the therapeutic index. Second, we propose that curbing tumor drug resistance is another important consequence of using promoter drugs. In particular, we discuss evidence suggesting that promoter drugs can (i) prevent induction of new resistance by paracrine factors released in response to effector drugs, and (ii) reverse existing drug resistance induced by mechanical cues and tumor-cell-extracellular-matrix interactions.
我们在这里称之为“促进剂药物”的几类药物可以提高我们称之为“效应剂药物”的其他药物的肿瘤摄取和穿透率，这些药物发挥直接的抗肿瘤作用。在这篇综述中，我们讨论了使用促进剂药物可以获得的主要治疗优势。首先，通过使用促进剂药物，可以特异性地增强效应药物在肿瘤中的积累，而正常组织中的积累不变，从而提高治疗指数。其次，我们提出抑制肿瘤药物耐药性是使用促进剂药物的另一个重要后果。特别是，我们讨论了一些证据表明，促进剂药物可以（i）防止由于效应药物释放的旁分泌因子而引起的新的耐药性的诱导，以及（ii）逆转由机械线索和肿瘤细胞-细胞外基质相互作用引起的现有耐药性。
